Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07216313 | A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants | PHASE1 | COMPLETED | 40 | — | — | Sep 30, 2025 | Oct 20, 2025 | Jan 23, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Effect of resmetirom on pharmacokinetics of denifanstat |
| Cohort 2 | EXPERIMENTAL | Effect of denifanstat on pharmacokinetics of resmetirom |
| Name | Type | Description |
|---|---|---|
| Denifanstat | DRUG | Once daily |
| Resmetirom | DRUG | Once daily |
Additional inclusion and exclusion criteria may apply. Inclusion Criteria: * Seated blood pressure is ≥ 90/40 mmHg and ≤ 140/90 mmHg at the screening visit. * Seated pulse rate is ≥ 40 bpm and ≤ 99 bpm at the screening visit. * QTcF interval is ≤ 460 msec (males) and ≤ 470 msec (females) and has E...